Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity

Dowden H , Munro J . Trends in clinical success rates and therapeutic focus. Nat. Rev. Drug Discov . 2019 Jul; 18(7): 495–496. DOI: 10.1038/d41573-019-00074-z. PMID: 31267067. https://doi.org/10.1038/d41573-019-00074-z

Harrison RK . Phase II and phase III failures: 2013–2015. Nat. Rev. Drug. Discov. , 2016 Dec; 15(12): 817–818. DOI: 10.1038/nrd.2016.184. Epub 2016 Nov 4. PMID: 27811931. https://doi.org/10.1038/nrd.2016.184

Laverty H , Benson C , Cartwright E , et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. Br. J. Pharmacol. , 2011 Jun; 163(4): 675–693. DOI: 10.1111/j.1476-5381.2011.01255.x. PMID: 21306581; PMCID: PMC3111672. https://doi.org/10.1111/j.1476-5381.2011.01255.x

Mayo Foundation for Medical Education and Research. Long QT syndrome. Accessed Jan 18, 2024. https://www.mayoclinic.org/diseases-conditions/long-qt-syndrome/symptoms-causes/syc-20352518

Cohagan B , Brandis D . Torsade de Pointes. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023 Aug 8. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459388/

Li D , Chai S , Wang H , et al. Drug-induced QT prolongation and torsade de pointes: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database. Front. Pharmacol. , 2023 Dec 21; 14: 1259611. DOI: 10.3389/fphar.2023.1259611. PMID: 38186652; PMCID: PMC10771307. https://doi.org/10.3389/fphar.2023.1259611

Krumpholz L , Wiśniowska B , Polak S . Correction to: Open-access database of literature derived drug-related Torsade de Pointes cases. BMC Pharmacol. Toxicol. , 2022 Jan 31; 23(1): 11. DOI: 10.1186/s40360-022-00550-0. Erratum for: BMC Pharmacol. Toxicol. 2022 Jan 10; 23(1): 7. PMID: 35101142; PMCID: PMC8802418. https://doi.org/10.1186/s40360-022-00550-0

Qu Y , Kirby R , Davies R , et al. Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in hERG Assays. Nucleic Acid Ther. , 2023 Apr; 33(2): 132–140. DOI: 10.1089/nat.2022.0043. Epub 2022 Dec 26. PMID: 36576986; PMCID: PMC10066779. https://doi.org/10.1089/nat.2022.0043

GLP hERG Screening. 2023. http://www.metrionbiosciences.com/GLP-herg-screening

Zeng H , Kang J . In vitro Testing of Proarrhythmic Toxicity. In: Zhang D , Surapaneni S , eds. ADME-Enabling Technologies in Drug Design and Development . Hoboken, NJ: John Wiley & Sons; 2012. https://doi.org/10.1002/9781118180778.ch32

Masterton J , Tokar S , Jinat A , Kirby R . (2024). GLP hERG Assay Validation following ICH E14/S7B 2022 Q&A best practice guidelines. Posted 2024 Feb 1. Accessed 2024 Apr 2. https://www.metrionbiosciences.com/wp-content/uploads/2024/02/Metrion-GLP-poster_01.02.2024.pdf

Shah RR . The significance of QT interval in drug development. Br. J. Clin. Pharmacol . 2002 Aug; 54(2): 188–202. DOI: 10.1046/j.1365-2125.2002.01627.x. PMID: 12207642; PMCID: PMC1874403. https://doi.org/10.1046/j.1365-2125.2002.01627.x

Turner JR , Karnad DR , Cabell CH , Kothari S . Recent developments in the science of proarrhythmic cardiac safety of new drugs. Eur. Heart J. Cardiovasc. Pharmacother. , 2017 Apr 1; 3(2): 118–124. DOI: 10.1093/ehjcvp/pvw045. PMID: 28363206. https://doi.org/10.1093/ehjcvp/pvw045

Callahan T . The Future of QT in Clinical Trials. App. Clin. Trials . 2014 Sept 22. https://www.appliedclinicaltrialsonline.com/view/future-qt-clinical-trials